Colon Cancer

2007 ◽  
Vol 5 (9) ◽  
pp. 884 ◽  
Author(s):  
_ _
Keyword(s):  
Colon Cancer ◽  
Clinical Presentation ◽  
The United States ◽  
Care Physician ◽  
Treatment Modalities ◽  
The Third ◽  
The Past ◽  
Colon And Rectal Cancer ◽  
Pathologic Staging ◽  
Recent Version

Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States. An estimated 112,340 new cases of colon cancer will occur in 2007 and an estimated 52,180 people will die from colon and rectal cancer in the same year. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. These guidelines begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org

Colon Cancer Clinical Practice Guidelines in Oncology

2005 ◽  
Vol 3 (4) ◽  
pp. 468 ◽  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Recurrent Disease ◽  
The United States ◽  
Treatment Modalities ◽  
Men And Women ◽  
Nccn Guidelines ◽  
The Third ◽  
The Past ◽  
Recent Version

Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States, and in 2005, an estimated 104,950 new cases of colon cancer will occur. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. The NCCN guidelines summarize the management of colon cancer, from disease presentation through management of recurrent disease and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Colon Cancer Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (1) ◽  
pp. 40 ◽  
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
The United States ◽  
Treatment Modalities ◽  
Comprehensive Management ◽  
The Past ◽  
Management Algorithm ◽  
Recent Version

Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States, and in 2002, an estimated 107,300 new cases of colon cancer will have occurred. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. The NCCN clinical practice guidelines for managing colon cancer discuss these advances and provide a comprehensive management algorithm. For the most recent version of the guidelines, please visit NCCN.org

Anal Canal Cancer Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (1) ◽  
pp. 64 ◽  
Keyword(s):  
Clinical Practice ◽  
Anal Canal ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Digestive System ◽  
Clinical Presentation ◽  
The United States ◽  
Anal Canal Cancer ◽  
Pathologic Staging ◽  
Recent Version

An estimated 3,900 new cases of anal canal cancer will occur in 2002, accounting for approximately 1.6% of digestive system cancers in the United States. NCCN clinical practice guidelines for managing anal cancer discuss the complete management of this disease, from clinical presentation through diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Rectal Cancer Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (1) ◽  
pp. 54 ◽  
Keyword(s):  
Primary Care ◽  
Rectal Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Adjuvant Treatment ◽  
Clinical Presentation ◽  
Care Physician ◽  
Pathologic Staging ◽  
Recent Version

This article summarizes the NCCN clinical practice guidelines for managing rectal cancer. The guidelines begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org

Esophageal Cancer Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (1) ◽  
pp. 14 ◽  
Keyword(s):  
Primary Care ◽  
Esophageal Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Adjuvant Treatment ◽  
Clinical Presentation ◽  
Care Physician ◽  
Pathologic Staging ◽  
Recent Version

This article summarizes the NCCN clinical practice guidelines for managing esophageal cancer. The guidelines begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org

Fifty Years of Experience with Chordomas in Southeast Scotland

Neurosurgery ◽  
1985 ◽  
Vol 16 (2) ◽  
pp. 166-170 ◽  
Author(s):  
P. O'Neill ◽  
B.A. Bell ◽  
J.D. Miller ◽  
I. Jacobson ◽  
W. Guthrie
Keyword(s):  
Clinical Presentation ◽  
Surgical Intervention ◽  
Slow Growth ◽  
Multicenter Trial ◽  
Treatment Modalities ◽  
Therapeutic Approaches ◽  
Slow Growth Rate ◽  
The Past ◽  
New Therapeutic Approaches

Abstract We report the clinical presentation and management of 34 patients with a histologically proven chordoma, treated in the neurosurgical departments in Edinburgh and Dundee, over the past 50 years. Although these tumors are commonly regarded as being locally invasive with a variable, but generally slow growth rate, they can metastasize, and this may precede surgical intervention, as in one of our patients. Our cases are compared to those in previously published series, and a comprehensive review of the treatment modalities for tumors at various sites is presented. The optimal treatment to be recommended from our own experience, and that of others, is aggressive operation and radiotherapy. A combination of hyperthermia and chemotherapy has shown some promise, but remains untested, and highlights the need for a multicenter trial with long follow-up to allow the evaluation of new therapeutic approaches.

Rectal Cancer Clinical Practice Guidelines in Oncology

2005 ◽  
Vol 3 (4) ◽  
pp. 492 ◽  
Keyword(s):  
Rectal Cancer ◽  
Colon Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Multidisciplinary Approach ◽  
The Past ◽  
Recent Version ◽  
The U.S ◽  
Cancer Panel

In 2005, an estimated 40,340 new cases of rectal cancer will occur in the U.S., and experts estimate that during the same year, 56,290 people will die of rectal and colon cancer. As with colon cancer, however, mortality from rectal cancer has also decreased over the past 30 years. The NCCN Rectal Cancer Panel believes a multidisciplinary approach is necessary for effectively managing rectal cancer, an approach detailed here. For the most recent version of the guidelines, please visit NCCN.org

Ovarian Cancer

2008 ◽  
Vol 6 (8) ◽  
pp. 766 ◽  
Author(s):  
_ _
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Presentation ◽  
Advanced Disease ◽  
Gynecologic Cancer ◽  
The United States ◽  
Epidemiologic Studies ◽  
Nccn Guidelines ◽  
New Information ◽  
Recent Version

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer and the fifth most common cause of cancer mortality in women in the United States. Fewer than 40% of women with ovarian cancer are cured, and 70% of patients present with advanced disease; because of the location of the ovaries, ovarian cancer has been difficult to diagnose at earlier stages. Epidemiologic studies have identified risk factors, including family history. The NCCN guidelines discuss epithelial ovarian cancer as well as less common ovarian histopathologies, including germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumors of the ovary), and ovarian stromal tumors. For 2008, updates include the addition of platinum-based combination therapy as a possible treatment modality for recurrence and a listing of preferred agents for acceptable recurrence modalities. New information was also added to the section on clinical presentation. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Nuclear targeting of gold nanoparticles

2021 ◽  
Author(s):  
Celina Yang
Keyword(s):  
Cancer Research ◽  
Gold Nanoparticles ◽  
Therapy Response ◽  
Drug Carriers ◽  
Treatment Modalities ◽  
Cancer Drug ◽  
Nuclear Targeting ◽  
The Third ◽  
The Past ◽  
Anti Cancer

Gold nanoparticles (GNPs) have been extensively used in cancer research due to their abilities as anti-cancer drug carriers for chemotherapy and as dose enhancers in radiotherapy. Although most GNP research in the past involved cytoplasm localized GNPs, it is predicted that therapy response can be enhanced if GNPs can be effectively targeted into the nucleus. A strategy for designing a GNP-peptide complex for targeting the nucleus will be presented. Three different sequences of peptides (CKKKKKKGGAGDMFG, CGGRKKRRGRRRAP, CALNN) were conjugated onto GNPs. The first peptide was used to stabilize the complex, the second peptide to enhance uptake into the cell, while the third peptide was used to induce nuclear delivery. With nuclear targeting, more damage can be caused to the DNP of cancer cells upon irradiation. This research will establish a more successful NP-based platform that combines treatment modalities and more effectively approach cancer treatment.

Liver Transplantation for Hepatocellular Carcinoma: An Update

2006 ◽  
Vol 4 (8) ◽  
pp. 762-767 ◽  
Author(s):  
Jean F. Botha ◽  
Alan N. Langnas
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Selection Criteria ◽  
Hepatic Cirrhosis ◽  
The United States ◽  
Treatment Modalities ◽  
Hepatic Malignancy ◽  
The Third ◽  
Small Hcc

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and the most common primary hepatic malignancy. It arises on a background of hepatic cirrhosis in approximately 95% of the cases in the United States. A wide variety of treatment modalities have been applied in the treatment of HCC. Liver transplantation has emerged as the preferred treatment for patients with small HCC. Transplantation for patients whose tumors do not exceed the Milan criteria yields results equivalent to those of transplantation for non-HCC indications. Controversy now exists regarding the use of living donors, expansion of selection criteria, and role of adjuvant therapy.

Sign in / Sign up

Export Citation Format

Share Document